Uncategorized
Guidance pending in 2016 for treatment of central retinal vein occlusion
WAIKOLOA, Hawaii — Likening the SCORE2 trial to the CATT trial and the LEAVO trial to the IVAN trial, Michael S. Ip, MD, anticipates the retina community will have some guidance regarding which treatments to use for central retinal vein occlusion when the SCORE2 and LEAVO trials yield results.“I think the comparative effectiveness research trials SCORE and LEAVO will help guide us in the future with best first-line and second-line therapies [for CRVO],” Ip said at Retina 2016.